7/105 sources · 5 publishersUpdated Nov 16, 22:37 UTC
Eli Lilly’s Zepbound shows strong BMI reductions in adolescent obesity trial
Eli Lilly reported results from the phase‑3 SURMOUNT‑ADOLESCENTS trial, which enrolled 160 participants aged 12‑17 with obesity. Over 72 weeks, tirzepatide (Zepbound) lowered BMI by 18.5% – 21.4% versus a 0.5% increase on placebo, and 48.1% of treated teens achieved a ≥20% BMI drop. Most adolescents experienced gastrointestinal side effects, and the drug is not yet FDA‑approved for patients under 18.
Why it matters
The data suggest Zepbound could become a new therapeutic option for teen obesity, potentially expanding Lilly’s market beyond adults; however, approval is pending and insurers currently do not cover off‑label use.
Key facts
- 1The trial enrolled 160 adolescents aged 12‑17 with obesity or overweight and at least one obesity‑related condition. medicaldaily.com
- 2BMI fell an average of 21.4% on tirzepatide and rose 0.5% on placebo (treatment‑estimand). medicaldaily.com
- 3When counting all participants, including dropouts, BMI fell 18.5% on tirzepatide and rose 0.5% on placebo. medicaldaily.com
- 4Body weight decreased by about 17.8 kg (≈39 lb) in the tirzepatide group, while the placebo group gained 2.3 kg. medicaldaily.com
- 595.4% of tirzepatide‑treated teens reported any adverse event, most commonly nausea, vomiting or diarrhea; 9.3% stopped treatment because of side effects. medicaldaily.com
- 648.1% of adolescents on tirzepatide achieved a ≥20% BMI reduction at 72 weeks, versus 7.9% on placebo. healio.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.